المؤلفون: Martino EA; Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy., Palmieri S; Hematology Unit, Ospedale Cardarelli, Napoli, Italy., Galli M; Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni, Bergamo, Italy., Derudas D; Department of Hematology, Businco Hospital, Cagliari, Italy., Mina R; Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy., Della Pepa R; Department of Clinical Medicine and Surgery, Hematology Unit, University of Naples 'Federico II', Naples, Italy., Zambello R; Department of Medicine, University of Padova, Hematology Unit, Padova, Italy.; Veneto Institute of Molecular Medicine, Padova, Italy., Vigna E; Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy., Bruzzese A; Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy., Mangiacavalli S; Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy., Zamagni E; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Califano C; Onco-Hematology Unit, 'A. Tortora' Hospital, Pagani, Italy., Musso M; Department of Oncology, Onco-Hematology Unit and TMO U.O.C., Palermo, Italy., Conticello C; Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy., Cerchione C; Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Mele G; Department of Hematology, Hospital Perrino, Brindisi, Italy., Di Renzo N; Department of Hematology, Hospital Vito Fazzi, Lecce, Italy., Offidani M; Hematology Unit, AOU delle Marche, Ancona, Italy., Tarantini G; Hematology Unit, 'Dimiccoli' Hospital, Barletta (BAT), Italy., Casaluci GM; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy., Rago A; UOSD Ematologia, Rome, Italy., Ria R; Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro Medical School, Internal Medicine 'G. Baccelli'; CITEL, Bari, Italy.; Interdepartmental Centre for Research in Telemedicine, University of Bari Aldo Moro, Bari, Italy., Uccello G; Hematology Department, G. Garibaldi Hospital, Catania, Italy., Barilà G; Hematology Unit, Ospedale San Bortolo, Vicenza, Italy., Palumbo G; Department of Hematology, Hospital University Riuniti, Foggia, Italy., Pettine L; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy., Vincelli ID; Department of Hemato-Oncology and Radiotherapy, Hematology Unit, Great Metropolitan Hospital 'Bianchi-Melacrino-Morelli', Reggio Calabria, Italy., Brunori M; Internal Medicine, Ospedale Santa Croce, Fano, Italy., Accardi F; Department of Hematology I, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy., Amico V; UOSD Ematologia, AORN San Pio, Benevento, Italy., Amendola A; Hematology Unit, Azienda Ospedaliera Regionale 'San Carlo', Potenza, Italy., Fontana R; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Bongarzoni V; Department of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy., Rossini B; Hematology and Cell Therapy Unit, IRCCS Istituto Tumori 'Giovanni Paolo II' Bari, Bari, Italy., Cotzia E; Section of Hematology- Ospedale E. Muscatello-Augusta, Siracusa, Italy., Gozzetti A; Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy., Rizzi R; Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico Bari, Bari, Italy.; Department of Precision and Regenerative Medicine and Ionian Area, 'Aldo Moro' University School of Medicine, Bari, Italy., Sgherza N; Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico Bari, Bari, Italy., Reddiconto G; Department of Hematology, Hospital Vito Fazzi, Lecce, Italy., Maroccia A; Hematology Unit - Ospedale dell'Angelo Azienda ULSS n.3 Serenissima, Venezia Mestre, Italy., Franceschini L; Lymphoproliferative Diseases Unit, Tor Vergata University Hospital, Rome, Italy., Bertuglia G; Dipartimento di Oncologia ed Ematologia SC Ematologia 1 A.O. Citta' della Salute e della Scienza di Torino P.O. Molinette, Torino, Italy., Nappi D; Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Barbieri E; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy., Gamberi B; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy., Petrucci MT; Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Rome, Italy., Di Raimondo F; Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Catania, Italy., Neri A; Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy., Morabito F; Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy., Musto P; Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico Bari, Bari, Italy.; Department of Precision and Regenerative Medicine and Ionian Area, 'Aldo Moro' University School of Medicine, Bari, Italy., Gentile M; Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

المصدر: Hematological oncology [Hematol Oncol] 2024 Jul; Vol. 42 (4), pp. e3290.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/mortality , Multiple Myeloma*/pathology , Dexamethasone*/administration & dosage , Dexamethasone*/adverse effects , Dexamethasone*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Thalidomide*/analogs & derivatives , Thalidomide*/administration & dosage , Thalidomide*/adverse effects , Thalidomide*/therapeutic use, Humans ; Male ; Female ; Aged ; Middle Aged ; Retrospective Studies ; Follow-Up Studies ; Aged, 80 and over ; Adult ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Drug Resistance, Neoplasm ; Survival Rate

مستخلص: The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18-month follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three-fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow-up. In conclusion, our real-world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.
(© 2024 John Wiley & Sons Ltd.)

المؤلفون: Yiu TH; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Ko Y; School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Pudipeddi A; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Natale P; School of Public Health, University of Sydney, Sydney, New South Wales, Australia.; Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro, Bari, Italy.; Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Leong RW; Gastrointestinal and Liver Services Research Unit, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.

المصدر: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Jul; Vol. 60 (1), pp. 103-104. Date of Electronic Publication: 2024 May 23.

نوع المنشور: Letter

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Crohn Disease*/drug therapy , Antibodies, Monoclonal*/therapeutic use, Humans ; United Arab Emirates ; Treatment Outcome

المؤلفون: von Kobyletzki LB; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.; School of Medical Sciences, Örebro University, Örebro, Sweden., Ulriksdotter J; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Sukakul T; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Aerts O; Contact Allergy Unit, Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, University of Antwerp, Antwerp, Belgium., Agner T; Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark., Buhl T; Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany., Bruze M; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Foti C; Section of Dermatology, DIMEPREJ Department, University 'Aldo Moro', Bari, Italy., Gimenez-Arnau A; Department of Dermatology, Hospital del Mar and Research Institute de Barcelona, Universitat Pompeu Fabra, Barcelona, Spain., Gonçalo M; Clinic of Dermatology, Coimbra University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Hamnerius N; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden., Johansen JD; Department of Dermatology, Herlev and Gentofte Hospital, Copenhagen, Denmark., Rustemeyer T; Dermato-Allergology and Occupational Dermatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Stingeni L; Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy., Wilkinson M; Leeds Teaching Hospitals, NHS Trust, Leeds, UK., Svedman C; Department of Occupational and Environmental Dermatology, Lund University, Skåne University Hospital, Malmö, Sweden.

المصدر: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jul; Vol. 38 (7), pp. 1329-1346. Date of Electronic Publication: 2024 Feb 23.

نوع المنشور: Journal Article; Systematic Review; Review

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 1*/complications , Diabetes Mellitus, Type 1*/epidemiology , Dermatitis, Allergic Contact*/epidemiology , Dermatitis, Allergic Contact*/etiology , Dermatitis, Allergic Contact*/diagnosis, Humans ; Prevalence ; Child ; Adult ; Blood Glucose Self-Monitoring/instrumentation ; Insulin Infusion Systems/adverse effects ; Surveys and Questionnaires ; Incidence

مستخلص: Use of medical devices (MDs), that is, glucose sensors and insulin pumps, in patients with Type 1 diabetes mellitus (T1D) has proven an enormous advantage for disease control. Adverse skin reactions from these MDs may however hamper compliance. The objective of this study was to systematically review and analyse studies assessing the prevalence and incidence of dermatitis, including allergic contact dermatitis (ACD) related to MDs used in patients with T1D and to compare referral routes and the clinical investigation routines between clinics being part of the European Environmental and Contact Dermatitis Research Group (EECDRG). A systematic search of PubMed, EMBASE, CINAHL and Cochrane databases of full-text studies reporting incidence and prevalence of dermatitis in persons with T1D using MDs was conducted until December 2021. The Newcastle-Ottawa Scale was used to assess study quality. The inventory performed at EECRDG clinics focused on referral routes, patient numbers and the diagnostic process. Among the 3145 screened abstracts, 39 studies fulfilled the inclusion criteria. Sixteen studies included data on children only, 14 studies were on adults and nine studies reported data on both children and adults. Participants were exposed to a broad range of devices. Skin reactions were rarely specified. It was found that both the diagnostic process and referral routes differ in different centres. Further data on the prevalence of skin reactions related to MDs in individuals with T1D is needed and particularly studies where the skin reactions are correctly diagnosed. A correct diagnosis is delayed or hampered by the fact that, at present, the actual substances within the MDs are not declared, are changed without notice and the commercially available test materials are not adequately updated. Within Europe, routines for referral should be made more standardized to improve the diagnostic procedure when investigating patients with possible ACD from MDs.
(© 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)

المؤلفون: Maiorano MFP; Obstetrics and Gynaecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy., Messina C; Oncology Unit, ARNAS Civico, Palermo, Italy., Maiello E; Oncology Unit, Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy., Cormio G; Gynaecologic Oncology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.; Department of Interdisciplinary Medicine (DIM), University of Bari, Bari, Italy., Maiorano BA; Oncology Unit, Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy.

المصدر: BJOG : an international journal of obstetrics and gynaecology [BJOG] 2024 Jul; Vol. 131 (8), pp. 1157-1159. Date of Electronic Publication: 2024 Jan 02.

نوع المنشور: Journal Article; Meta-Analysis

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100935741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-0528 (Electronic) Linking ISSN: 14700328 NLM ISO Abbreviation: BJOG Subsets: MEDLINE

مواضيع طبية MeSH: Endometrial Neoplasms*/drug therapy , Endometrial Neoplasms*/genetics , Immune Checkpoint Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Randomized Controlled Trials as Topic* , Progression-Free Survival*, Humans ; Female

مستخلص: Objective: The combination of immune checkpoint inhibitors (ICIs) plus chemotherapy is currently being tested as the first-line treatment of advanced endometrial. We aimed to evaluate the efficacy and safety of this combination.
Design: We performed a meta-analysis of randomized clinical trials.
Population and Setting: Patients with advanced endometrial carcinoma receiving ICIs plus chemotherapy in the experimental arm, compared with chemotherapy plus placebo in the control arm, were included.
Methods and Outcomes: We evaluated the progression-free survival (PFS) as an efficacy outcome and the number and grades of adverse events (AEs) for safety. Hazard ratios (HR) for PFS and risk ratios (RR) for AEs, with 95% confidence intervals (CI), were calculated.
Results: 1303 patients were treated in the included studies. Adding ICIs to chemotherapy significantly improved PFS in mismatch repair deficient (dMMR-HR 0.29; 95% CI, 0.20-0.42; p < 0.00001) and in mismatch repair proficient (pMMR-HR 0.64; 95% CI, 0.46-0.90; p = 0.01) patients. No difference emerged for all-grades AEs (RR 1.00; p = 0.98), but the risk of ≥G3 AEs was increased in the ICIs + chemotherapy group (RR 1.22; 95% CI, 1.11-1.34; p < 0.0001).
Conclusions: Adding ICIs to chemotherapy significantly improves PFS in first-line endometrial cancer, regardless of MMR status.
(© 2024 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.)

المؤلفون: Rocca B; Department of Safety and Bioethics, Section of Pharmacology, Catholic University School of Medicine, Rome, Italy.; Department NeuroFarBa, University of Florence, Florence, Italy., Tosetto A; Hematology Department, San Bortolo Hospital, Vicenza, Italy., Petrucci G; Department of Safety and Bioethics, Section of Pharmacology, Catholic University School of Medicine, Rome, Italy.; Department of Radiological and Hematological Sciences, Section of Hematology, Catholic University School of Medicine, Roma, Italy., Rossi E; Department of Radiological and Hematological Sciences, Section of Hematology, Catholic University School of Medicine, Roma, Italy.; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy., Betti S; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy., Soldati D; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy., Iurlo A; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy., Cattaneo D; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy., Bucelli C; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy., Dragani A; Hematology Unit, Department of Oncology and Hematology, Ospedale Civile 'Santo Spirito', Pescara, Italy., Di Ianni M; Hematology Unit, Department of Oncology and Hematology, Ospedale Civile 'Santo Spirito', Pescara, Italy.; Department of Medicine and Aging Sciences, 'G. D'Annunzio' University, Chieti, Italy., Ranalli P; Hematology Unit, Department of Oncology and Hematology, Ospedale Civile 'Santo Spirito', Pescara, Italy.; Department of Medicine and Aging Sciences, 'G. D'Annunzio' University, Chieti, Italy., Palandri F; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Vianelli N; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Beggiato E; Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy., Lanzarone G; Department of Oncology, Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy., Ruggeri M; Hematology Department, San Bortolo Hospital, Vicenza, Italy., Carli G; Hematology Department, San Bortolo Hospital, Vicenza, Italy., Elli EM; Division of Haematology and Bone Marrow Transplantation Unit, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy., Renso R; Division of Haematology and Bone Marrow Transplantation Unit, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy., Randi ML; Department of Medicine-DIMED, University of Padova, Padova, Italy., Bertozzi I; Department of Medicine-DIMED, University of Padova, Padova, Italy., Loscocco GG; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy., Ricco A; Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico, Bari, Italy., Specchia G; University of Bari Aldo Moro, Bari, Italy., Vannucchi AM; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy., Rodeghiero F; Hematology Project Foundation, Affiliated to the Department of Hematology, San Bortolo Hospital, Vicenza, Italy., De Stefano V; Department of Radiological and Hematological Sciences, Section of Hematology, Catholic University School of Medicine, Roma, Italy.; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy., Patrono C; Department of Safety and Bioethics, Section of Pharmacology, Catholic University School of Medicine, Rome, Italy.; Center of Excellence on Aging, 'G. D'Annunzio' University School of Medicine, Chieti, Italy.

مؤلفون مشاركون: Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators

المصدر: American journal of hematology [Am J Hematol] 2024 Jun 15. Date of Electronic Publication: 2024 Jun 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

مستخلص: Patients with essential thrombocythemia (ET) are treated with once-daily low-dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short-term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice-daily aspirin dosing restores persistent platelet thromboxane (TX) inhibition. However, the long-term pharmacodynamic efficacy, safety and tolerability of twice-daily aspirin remain untested. We performed a multicenter, randomized, open-label, blinded-endpoint, phase-2 trial in which 242 patients with ET were randomized to 100 mg aspirin twice- or once-daily and followed for 20 months. The primary endpoint was the persistence of low serum TXB 2 , a surrogate biomarker of antithrombotic efficacy. Secondary endpoints were major and clinically relevant non-major bleedings, serious vascular events, symptom burden assessed by validated questionnaires, and in vivo platelet activation. Serum TXB 2 was consistently lower in the twice-daily versus once-daily regimen on 10 study visits over 20 months: median 3.9 ng/mL versus 19.2 ng/mL, respectively; p < .001; 80% median reduction; 95% CI, 74%-85%. No major bleeding occurred. Clinically relevant non-major bleedings were non-significantly higher (6.6% vs. 1.7%), and major thromboses lower (0.8% vs. 2.5%) in the twice-daily versus once-daily group. Patients on the twice-daily regimen had significantly lower frequencies of disease-specific symptoms and severe hand and foot microvascular pain. Upper gastrointestinal pain was comparable in the two arms. In vivo platelet activation was significantly reduced by the twice-daily regimen. In patients with ET, twice-daily was persistently superior to once-daily low-dose aspirin in suppressing thromboxane biosynthesis and reducing symptom burden, with no detectable excess of bleeding and gastrointestinal discomfort.
(© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.)

المؤلفون: Del Prato S; Interdisciplinary Research Center 'Health Science' of the Sant'Anna School of Advanced Studies, Pisa, Italy., Giorgino F; Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy., Szafranski K; Eversana, Burlington, Ontario, Canada., Poon Y; Abbott Diabetes Care, Alameda, California, USA.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Jun 10. Date of Electronic Publication: 2024 Jun 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مستخلص: Aims: To assess the cost-utility of the FreeStyle Libre flash continuous glucose monitoring (CGM) system from an Italian healthcare system perspective, when compared with self-monitoring of blood glucose (SMBG) in people living with type 2 diabetes mellitus (T2DM) receiving basal insulin.
Materials and Methods: A patient-level microsimulation model was run using Microsoft Excel for 10 000 patients over a lifetime horizon, with 3.0% discounting for costs and utilities. Inputs were based on clinical trials and real-world evidence, with patient characteristics reflecting Italian population data. The effect of flash CGM was modelled as a persistent 0.8% reduction in glycated haemoglobin versus SMBG. Costs (€ 2023) and disutilities were applied to glucose monitoring, diabetes complications, severe hypoglycaemia, and diabetic ketoacidosis. The health outcome was measured as quality-adjusted life-years (QALYs).
Results: Direct costs were €5338 higher with flash CGM than with SMBG. Flash CGM was associated with 0.51 more QALYs than SMBG, giving an incremental cost-effectiveness ratio (ICER) of €10 556/QALY. Scenario analysis ICERs ranged from €3825/QALY to €26 737/QALY. In probabilistic analysis, flash CGM was 100% likely to be cost effective at willingness-to-pay thresholds > €20 000/QALY.
Conclusions: From an Italian healthcare system perspective, flash CGM is cost effective compared with SMBG for people living with T2DM on basal insulin.
(© 2024 John Wiley & Sons Ltd.)

المؤلفون: Scilletta S; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Leggio S; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Di Marco M; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Miano N; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Musmeci M; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Marrano N; Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy., Natalicchio A; Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy., Giorgino F; Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy., Bosco G; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Di Giacomo Barbagallo F; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Scamporrino A; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Di Mauro S; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Filippello A; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Scicali R; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Russello M; Hepatology Unit, ARNAS Garibaldi, Catania, Italy., Spadaro L; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Purrello F; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Piro S; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Di Pino A; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.

المصدر: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2024 Jun 04. Date of Electronic Publication: 2024 Jun 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE

مستخلص: Background and Aims: Cholemic nephropathy is a cause of acute kidney injury occurring in patients with jaundice. The aim of this study was to evaluate early renal function impairment in patients with mild acute hyperbilirubinemia in the absence of alterations of the common parameters used in clinical practice (serum creatinine or urea) and with normal renal morphology. We studied urinary biomarkers of tubular damage urinary neutrophil gelatinase-associated lipocalin (u-NGAL), urinary beta-2-microglobulin (u-B2M), urinary osteopontin (u-OPN), urinary trefoil factor 3 (u-TFF3) and urinary Cystatin C (u-Cys).
Methods: This is a case-control study investigating the following urinary biomarkers of tubular damage: u-NGAL, u-B2M, u-OPN, u-TFF3 and u-Cys, in patients with mild acute hyperbilirubinemia. Seventy-four patients were included in this study: 36 patients with jaundice and 38 patients without jaundice.
Results: Subjects with jaundice (total bilirubin 12.4 ± 7.3 mg/dL) showed higher u-NGAL, u-B2M, u-OPN, u-TFF3 and u-Cys compared with controls. After logistic regression analyses, including the following independent variables: age, estimated Glomerular Filtration Rate (eGFR), haemoglobin, diabetes, hypertension and jaundice, we observed a higher risk of elevated u-NGAL values (OR = 3.8, 95% CI 1.07-13.5, p = .03) and u-B2M (OR = 9.4, 95% CI 2.3-38.9, p = .0018) in jaundiced subjects. Moreover, urinary biomarkers had a direct correlation with serum cholestasis indexes.
Conclusions: This study demonstrated increased urinary biomarkers of tubular damage (u-NGAL, u-B2M, u-OPN, u-TFF3, and u-Cys) in patients with mild hyperbilirubinemia in comparison with a control group. These findings suggest early renal tubular damage in the absence of alterations of the normal parameters used in clinical practice (eGFR, serum urea and renal morphology).
(© 2024 The Author(s). Liver International published by John Wiley & Sons Ltd.)

المؤلفون: Coraducci F; Marche Polytechnic University, Ancona, Italy., De Zan G; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., Fedele D; Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda, Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna, Italy., Costantini P; Department of Radiology, Ospedale Universitario Maggiore della Carità di Novara, University of Eastern Piedmont, Novara, Italy., Guaricci AI; Department of Emergency and Organ Transplantation, Institute of Cardiovascular Disease, University Hospital Policlinico of Bari, Bari, Italy., Pavon AG; Division of Cardiology, Cardiocentro Ticino Institute Ente Ospedaliero Cantonale, Lugano, Switzerland., Teske A; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., Cramer MJ; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., Broekhuizen L; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., Van Osch D; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., Danad I; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., Velthuis B; Division of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands., Suchá D; Division of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Bilt I; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands.; Cardiology Department, HAGA Ziekenhuis, Den Haag, The Netherlands., Pizzi C; Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda, Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna, Italy., Russo AD; Marche Polytechnic University, Ancona, Italy., Oerlemans M; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., van Laake LW; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., van der Harst P; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands., Guglielmo M; Division Heart and Lung, Cardiology Department, University Medical Centre Utrecht, Utrecht, The Netherlands.; Cardiology Department, HAGA Ziekenhuis, Den Haag, The Netherlands.

المصدر: Echocardiography (Mount Kisco, N.Y.) [Echocardiography] 2024 Jun; Vol. 41 (6), pp. e15849.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8511187 Publication Model: Print Cited Medium: Internet ISSN: 1540-8175 (Electronic) Linking ISSN: 07422822 NLM ISO Abbreviation: Echocardiography Subsets: MEDLINE

مواضيع طبية MeSH: Heart Failure*/physiopathology , Heart Failure*/diagnosis, Humans ; Magnetic Resonance Imaging, Cine/methods

مستخلص: Heart failure (HF) is a chronic and progressive disease that often progresses to an advanced stage where conventional therapy is insufficient to relieve patients' symptoms. Despite the availability of advanced therapies such as mechanical circulatory support or heart transplantation, the complexity of defining advanced HF, which requires multiple parameters and multimodality assessment, often leads to delays in referral to dedicated specialists with the result of a worsening prognosis. In this review, we aim to explore the role of cardiac magnetic resonance (CMR) in advanced HF by showing how CMR is useful at every step in managing these patients: from diagnosis to prognostic stratification, hemodynamic evaluation, follow-up and advanced therapies such as heart transplantation. The technical challenges of scanning advanced HF patients, which often require troubleshooting of intracardiac devices and dedicated scans, will be also discussed.
(© 2024 The Author(s). Echocardiography published by Wiley Periodicals LLC.)

المؤلفون: Yiu TH; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Ko Y; Campbelltown and Camden Hospitals, Canterbury Hospital, Western Sydney University, Sydney, New South Wales, Australia.; Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Pudipeddi A; Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, New South Wales, Australia., Natale P; School of Public Health, University of Sydney, Sydney, New South Wales, Australia.; Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J), University of Bari Aldo Moro, Bari, Italy.; Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Leong RW; Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.

المصدر: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2024 Jun; Vol. 59 (11), pp. 1312-1334. Date of Electronic Publication: 2024 Apr 23.

نوع المنشور: Journal Article; Meta-Analysis; Systematic Review; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Gastrointestinal Agents*/therapeutic use , Antibodies, Monoclonal* , Pyrimidines*, Humans ; Ustekinumab/therapeutic use ; Crohn Disease/drug therapy ; Colitis, Ulcerative/drug therapy ; Inflammatory Bowel Diseases/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Observational Studies as Topic ; Infliximab/therapeutic use ; Piperidines/therapeutic use

مستخلص: Background: The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real-world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial year of treatment.
Aim: To provide real-world evidence on treatment effectiveness, tolerability and preferences of physicians and patients regarding various advanced therapies for IBD.
Methods: We conducted a systematic review of observational studies up to March 2023 assessing advanced therapies' persistence in UC and CD. Advanced therapies under examination included infliximab, adalimumab, vedolizumab, ustekinumab, golimumab, certolizumab and tofacitinib. We pooled the persistence of each agent and conducted a meta-analysis to compare the persistence of newer agents with traditional TNF inhibitors (TNFi)-specifically infliximab and adalimumab.
Results: Among 63 observational studies, vedolizumab had the highest 1-year persistence in UC (73.8%, 95% CI: 70.0%-77.6%) and ustekinumab in CD (77.5%, 95% CI: 72.9%-82.1%). Compared to TNFi, vedolizumab demonstrated increased persistence with a relative risk (RR) of 1.30 (95% CI: 1.19-1.41) for UC and 1.14 (95% CI: 1.09-1.20) for CD at 1 year, while ustekinumab demonstrated a RR of 1.15 (95% CI: 1.07-1.23) for CD at 1 year. Vedolizumab exhibited sustained increased persistence in UC over 2 years compared to TNFi (RR: 1.33, 95% CI 1.14-1.54).
Conclusion: This meta-analysis highlights the superior persistence of ustekinumab and vedolizumab over TNFi, and offers valuable insights for clinicians navigating the challenging landscape of UC and CD therapeutic choices.
(© 2024 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)

المؤلفون: Rodbard HW; Endocrine and Metabolic Consultants, Rockville, Maryland, USA., Barnard-Kelly K; Southern Health NHS Foundation Trust, Southampton, UK.; BHR Limited, Portsmouth, UK.; Spotlight Consultations, Fareham, UK., Pfeiffer AFH; Department of Endocrinology, Diabetes and Nutrition, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Germany., Mauersberger C; Sciarc GmbH, Baierbrunn, Germany., Schnell O; Sciarc GmbH, Baierbrunn, Germany.; Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany., Giorgino F; Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.

المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Jun; Vol. 26 (6), pp. 2029-2045. Date of Electronic Publication: 2024 Mar 21.

نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE

مواضيع طبية MeSH: Diabetes Mellitus, Type 2*/therapy , Diabetes Mellitus, Type 2*/complications , Obesity*/therapy , Obesity*/complications, Humans ; Weight Loss ; Healthy Lifestyle

مستخلص: The rising phenomenon of obesity, a major risk factor for the development and progression of type 2 diabetes, is a complex and multifaceted issue that requires a comprehensive and coordinated approach to be prevented and managed. Although novel pharmacological measures to combat obesity have achieved unprecedented efficacy, a healthy lifestyle remains essential for the long-term success of any therapeutic intervention. However, this requires a high level of intrinsic motivation and continued behavioural changes in the face of multiple metabolic, psychological and environmental factors promoting weight gain, particularly in the context of type 2 diabetes. This review is intended to provide practical recommendations in the context of a holistic, person-centred approach to weight management, including evidence-based and expert recommendations addressing supportive communication, shared decision-making, as well as nutritional and pharmacological therapeutic approaches to achieve sustained weight loss.
(© 2024 John Wiley & Sons Ltd.)